The worst Ebola virus disease outbreak in history ended in 2016 after infecting 28,600 people and killing about 11,300 worldwide.
The outbreak led to urgent action by medical experts across the world to combat this devastating disease; including the setting up of trials of vaccines to stop the disease taking hold.
This global commitment to develop a vaccine against the disease suggested eight options, out of a starting pool of 15 candidates, should be evaluated in clinical trials worldwide by the end of 2015.
Professor Sanjeev Krishna, of St George’s University of London’s Institute for Infection and Immunity, said: “An unprecedented Ebola outbreak showed how it is possible for academics, non-governmental organisations, industry and funders to work effectively together very quickly in times of medical crisis. The results of the trial show how a vaccine could best be used to tackle this terrible disease effectively.
“We need a system of specialists, medical experts and organisers that maintains vigilance against outbreak diseases like Ebola.
“We should continue to improve ways to make, evaluate and deliver vaccines when they are needed, often in parts of the world lacking in infrastructure for diagnosing infections and providing treatments.”
He explained that considering the persistent replication of the vaccine which is called rVSV-?GP-ZEBOV in children and adolescents, further studies investigating lower doses in this population are warranted.
The vaccine contains a non-infectious portion of a gene from the Zaire Ebola virus. The St George’s researchers worked with colleagues on a vaccine trial in Gabon.
In addition, lower vaccine doses should be considered when boosting individuals with pre-existing antibodies to Ebolavirus glycoprotein, a finding that has emerged after the vaccine was tested in a country that has experienced Ebolavirus outbreaks in the past.
The vaccine was one of two being examined as a ‘candidate’ option by the World Health Organisation to identify urgently a vaccine to combat the Ebola virus outbreak in West Africa.
The clinical trial was led by colleagues at University of Tübingen in Germany, coordinated by Professor Peter Kremsner with their partner institute CERMEL in Lambaréné, Gabon.
The Latest on: Ebola vaccine
- WHO welcomes crucial new funding for vaccineson June 4, 2020 at 8:54 am
WHO welcomes funding commitments made at today’s Global Vaccine Summit. The new pledges will enable Gavi to protect the next generation and reduce disease inequality by reaching an additional 300 ...
- 4 aspects of a fast-tracked COVID-19 vaccine that may complicate promotionon June 4, 2020 at 2:00 am
A rushed coronavirus vaccine could be a messaging minefield for medical marketers attempting to convince a wary public.
- 5 Promising Covid-19 Vaccines Now Selected For Trump’s Operation Warp Speedon June 3, 2020 at 11:27 pm
Five companies have now been picked by the Trump administration as the most likely candidates to produce a coronavirus vaccine, The New York Times reports.This comes as part of Operation Warp Speed ...
- COVID-19 vaccine may be ready by October, Pfizer CEO sayson June 3, 2020 at 7:07 pm
The vaccine is developing quickly through a scientific method not used before. It uses the genetic blueprint of the virus, rather than a killed or weakened virus ...
- Two more people infected with Ebola in new Congo outbreak, WHO sayson June 3, 2020 at 2:00 pm
The Ebola virus has infected two more people in Equateur province in western Democratic Republic of Congo and spread to a new area 150 km (93 miles) away from the original six cases, the World Heath ...
- J&J Gets Positive CHMP Opinion For Investigational Preventive Ebola Vaccine Regimenon May 29, 2020 at 6:43 am
Johnson & Johnson said that its Janssen Pharmaceutical Companies received a positive opinion from the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency or EMA for ...
- J&J's Ebola vaccine wins EU regulatory panel backingon May 29, 2020 at 5:37 am
J&J submitted its application to the European Medicines Agency (EMA) in November for the vaccine, which targets an Ebola strain that causes the disease in most people. The company in February said it ...
- European advisory group backs J&J Ebola vaccine regimenon May 29, 2020 at 5:34 am
The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval ofNYSE:JNJ) unit Janssen-Cilag International N.V.'s Ebola vaccine regim ...
- Johnson & Johnson Receives Positive CHMP Opinion for Janssen's Investigational Preventive Ebola Vaccine Regimenon May 29, 2020 at 3:57 am
The investigational Ebola vaccine regimen leverages Janssen's established AdVac® and PER.C6® technologies and Bavarian Nordic's MVA-BN® technology The AdVac® and ...
- Bavarian Nordic Announces that Janssen has Received Positive CHMP Opinion for its Investigational Preventative Ebola Vaccine Regimenon May 29, 2020 at 3:42 am
Bavarian Nordic A/S ((OMX: BAVA, OTC:BVNRY) announced today that its strategic partner Janssen Pharmaceutical Companies of Johnson ...
via Google News and Bing News